saracatinib
Showing 1 - 20 of 20
Alzheimer's Disease Trial in New Haven (saracatinib, Placebo)
Completed
- Alzheimer's Disease
- saracatinib
- Placebo
-
New Haven, ConnecticutYale Alzheimer's Disease Research Unit
Apr 22, 2021
Alcohol Drinking Trial in New Haven (Saracatinib, Placebos)
Completed
- Alcohol Drinking
- Saracatinib
- Placebos
-
New Haven, ConnecticutCMHC, Substance Abuse Center
Oct 20, 2020
Pulmonary Lymphangioleiomyomatosis Trial in United States (saracatinib)
Terminated
- Pulmonary Lymphangioleiomyomatosis
- saracatinib
-
Stanford, California
- +4 more
Jul 28, 2020
Alcohol Drinking Trial in New Haven (Saracatinib)
Completed
- Alcohol Drinking
- Saracatinib
-
New Haven, ConnecticutCMHC, Substance Abuse Center
Jan 10, 2020
Parkinson Disease Psychosis Trial in London (Saracatinib, Placebo Oral Tablet)
Unknown status
- Parkinson Disease Psychosis
- Saracatinib
- Placebo Oral Tablet
-
London, Camberwell, United KingdomMitul Mehta
Aug 12, 2019
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer Trial in Houston (saracatinib, laboratory
Terminated
- Adenocarcinoma of the Colon
- +5 more
- saracatinib
- laboratory biomarker analysis
-
Houston, TexasM D Anderson Cancer Center
Jul 29, 2019
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer Trial in Australia, Singapore, United
Completed
- Adenocarcinoma of the Pancreas
- +2 more
- saracatinib
- +5 more
-
Scottsdale, Arizona
- +8 more
Mar 20, 2019
Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer Trial in Canada, United
Completed
- Adenocarcinoma of the Gastroesophageal Junction
- +6 more
- saracatinib
-
Dalton, Georgia
- +4 more
Jul 26, 2018
Cancer Trial in Sheffield (Saracatinib, Placebo)
Completed
- Cancer
- Saracatinib
- Placebo
-
Sheffield, South Yorkshire, United KingdomSheffield Teaching Hospitals NHS Trust
Apr 12, 2018
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer Trial in Duarte (saracatinib, laboratory biomarker analysis)
Completed
- Hormone-resistant Prostate Cancer
- Recurrent Prostate Cancer
- saracatinib
- laboratory biomarker analysis
-
Duarte, CaliforniaCity of Hope
Mar 21, 2018
Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma Trial in Canada, United States (saracatinib)
Completed
- Adult Fibrosarcoma
- +14 more
- saracatinib
-
Rockledge, Pennsylvania
- +3 more
May 29, 2018
Extensive Stage Small Cell Lung Cancer, Lung Metastases, Malignant Pleural Effusion Trial in Rochester (saracatinib)
Completed
- Extensive Stage Small Cell Lung Cancer
- +3 more
- saracatinib
-
Rochester, MinnesotaNorth Central Cancer Treatment Group
Nov 2, 2017
Pulmonary Lymphangioleiomyomatosis Trial in Cincinnati, Houston (Saracatinib)
Completed
- Pulmonary Lymphangioleiomyomatosis
- Saracatinib
-
Cincinnati, Ohio
- +2 more
Nov 28, 2016
Invasive Thymoma and Thymic Carcinoma, Recurrent Thymoma and Thymic Carcinoma, Stage III Thymoma Trial in Stanford, Indianapolis
Terminated
- Invasive Thymoma and Thymic Carcinoma
- +4 more
- saracatinib
-
Stanford, California
- +1 more
Jun 5, 2015
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in United Kingdom (Paclitaxel, Saracatinib, Matched )
Completed
- Ovarian Cancer
- +2 more
- Paclitaxel
- +2 more
-
Cambridge, Cambridgeshire, United Kingdom
- +11 more
Apr 17, 2015
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer Trial in United States (saracatinib,
Terminated
- Hormone-resistant Prostate Cancer
- +2 more
- saracatinib
- hydrocortisone/placebo
-
Chicago, Illinois
- +14 more
Mar 18, 2015
Recurrent Melanoma, Stage IIA Melanoma, Stage IIB Melanoma Trial in Chicago (saracatinib)
Completed
- Recurrent Melanoma
- +4 more
- saracatinib
-
Chicago, IllinoisUniversity of Chicago Comprehensive Cancer Center
May 6, 2014
Estrogen Receptor-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer Trial in New York
Completed
- Estrogen Receptor-negative Breast Cancer
- +6 more
- saracatinib
- laboratory biomarker analysis
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Apr 2, 2014
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With
Completed
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
- +38 more
- saracatinib
- laboratory biomarker analysis
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Apr 2, 2014